Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) FCF Margin (2016 - 2025)

Historic FCF Margin for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to 32.56%.

  • Theravance Biopharma's FCF Margin fell 16600.0% to 32.56% in Q3 2025 from the same period last year, while for Sep 2025 it was 303.15%, marking a year-over-year increase of 3226300.0%. This contributed to the annual value of 18.43% for FY2024, which is 329100.0% up from last year.
  • As of Q3 2025, Theravance Biopharma's FCF Margin stood at 32.56%, which was down 16600.0% from 794.33% recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's FCF Margin registered a high of 794.33% during Q2 2025, and its lowest value of 1077.36% during Q1 2022.
  • Its 5-year average for FCF Margin is 170.75%, with a median of 96.65% in 2023.
  • Per our database at Business Quant, Theravance Biopharma's FCF Margin surged by 32345700bps in 2021 and then plummeted by -5749300bps in 2022.
  • Quarter analysis of 5 years shows Theravance Biopharma's FCF Margin stood at 305.73% in 2021, then plummeted by -178bps to 848.67% in 2022, then skyrocketed by 99bps to 8.72% in 2023, then soared by 33bps to 5.82% in 2024, then crashed by -459bps to 32.56% in 2025.
  • Its FCF Margin stands at 32.56% for Q3 2025, versus 794.33% for Q2 2025 and 279.69% for Q1 2025.